CRVO Stock — CervoMed Inc.: Cash, EV, Pipeline

Share price

$2.43

Market cap

$36.7M

Cash

$24.9M

Enterprise value

$11.8M

Balance sheet

Cash	$24.9M
Debt	$0.0M
Net cash	$24.9M
Enterprise value	$11.8M
Basic shares	13.5M shares
Fully diluted shares	28.3M shares
Fully diluted market cap	$68.7M
Cash per share	$1.84

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CRVO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	Neflamapimod	Phase 2	Nonfluent Variant Primary Progressive Aphasia (nfvPPA)	October 2026
Nov 11 - Dec 23	Neflamapimod	Phase 2	Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

neflamapimod

Phase 2 · Active Modality: small molecule (oral)

Aliases formerly VX-745

Target p38α (p38 MAPK)

Partnerships Vertex Pharmaceuticals: exclusive license to VX-745 (August 2012; option exercised 2014); up to ~$117M in regulatory and sales milestones plus sliding low- to mid-teen royalties on net sales; NIA grant of $21.3M funding the RewinD-LB Phase 2b trial

Indications

Dementia with Lewy bodies (DLB) (Phase 2)
Recovery after ischemic stroke (RESTORE trial) (Phase 2)
Nonfluent variant primary progressive aphasia (nfvPPA) (Phase 2)
ALS (EXPERTS-ALS platform) (Stage not disclosed)
Frontotemporal dementia (FTD) (Stage not disclosed)

Catalysts

— second half of 2026
— second half of 2026
— fourth quarter of 2026

Status note Lead and sole clinical candidate. Phase 2b RewinD-LB final results announced October 2025; FDA aligned November 2025 on planned single 32-week Phase 3 (~300 DLB patients without AD co-pathology). FDA Fast Track for DLB (October 2019); Orphan Drug Designation for FTD (November 2024). Strategic priority is securing a partnership to fund Phase 3.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06987643	Phase 2	Active, not recruiting	Collaborator	EIP Pharma Inc	—	Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke	—
NCT07033481	Phase 2	Active, not recruiting	Collaborator	EIP Pharma Inc	—	Nonfluent Variant Primary Progressive Aphasia (nfvPPA)	October 2026

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for EIP Pharma Inc on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

CRVO — CervoMed Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Active clinical trials